S&P 500   4,971.90 (-0.78%)
DOW   37,855.71 (+0.21%)
QQQ   417.33 (-1.44%)
AAPL   164.64 (-1.44%)
MSFT   400.51 (-0.93%)
META   484.41 (-3.47%)
GOOGL   154.09 (-1.23%)
AMZN   175.53 (-2.06%)
TSLA   149.51 (-0.28%)
NVDA   811.76 (-4.13%)
AMD   148.70 (-4.11%)
NIO   3.84 (-4.00%)
BABA   68.63 (-0.36%)
T   16.34 (+0.06%)
F   12.11 (+0.41%)
MU   107.36 (-4.08%)
GE   149.14 (-2.48%)
CGC   7.98 (+1.92%)
DIS   111.55 (-0.78%)
AMC   3.24 (+10.96%)
PFE   25.85 (+1.81%)
PYPL   62.03 (-0.11%)
XOM   120.11 (+1.34%)
S&P 500   4,971.90 (-0.78%)
DOW   37,855.71 (+0.21%)
QQQ   417.33 (-1.44%)
AAPL   164.64 (-1.44%)
MSFT   400.51 (-0.93%)
META   484.41 (-3.47%)
GOOGL   154.09 (-1.23%)
AMZN   175.53 (-2.06%)
TSLA   149.51 (-0.28%)
NVDA   811.76 (-4.13%)
AMD   148.70 (-4.11%)
NIO   3.84 (-4.00%)
BABA   68.63 (-0.36%)
T   16.34 (+0.06%)
F   12.11 (+0.41%)
MU   107.36 (-4.08%)
GE   149.14 (-2.48%)
CGC   7.98 (+1.92%)
DIS   111.55 (-0.78%)
AMC   3.24 (+10.96%)
PFE   25.85 (+1.81%)
PYPL   62.03 (-0.11%)
XOM   120.11 (+1.34%)
S&P 500   4,971.90 (-0.78%)
DOW   37,855.71 (+0.21%)
QQQ   417.33 (-1.44%)
AAPL   164.64 (-1.44%)
MSFT   400.51 (-0.93%)
META   484.41 (-3.47%)
GOOGL   154.09 (-1.23%)
AMZN   175.53 (-2.06%)
TSLA   149.51 (-0.28%)
NVDA   811.76 (-4.13%)
AMD   148.70 (-4.11%)
NIO   3.84 (-4.00%)
BABA   68.63 (-0.36%)
T   16.34 (+0.06%)
F   12.11 (+0.41%)
MU   107.36 (-4.08%)
GE   149.14 (-2.48%)
CGC   7.98 (+1.92%)
DIS   111.55 (-0.78%)
AMC   3.24 (+10.96%)
PFE   25.85 (+1.81%)
PYPL   62.03 (-0.11%)
XOM   120.11 (+1.34%)
S&P 500   4,971.90 (-0.78%)
DOW   37,855.71 (+0.21%)
QQQ   417.33 (-1.44%)
AAPL   164.64 (-1.44%)
MSFT   400.51 (-0.93%)
META   484.41 (-3.47%)
GOOGL   154.09 (-1.23%)
AMZN   175.53 (-2.06%)
TSLA   149.51 (-0.28%)
NVDA   811.76 (-4.13%)
AMD   148.70 (-4.11%)
NIO   3.84 (-4.00%)
BABA   68.63 (-0.36%)
T   16.34 (+0.06%)
F   12.11 (+0.41%)
MU   107.36 (-4.08%)
GE   149.14 (-2.48%)
CGC   7.98 (+1.92%)
DIS   111.55 (-0.78%)
AMC   3.24 (+10.96%)
PFE   25.85 (+1.81%)
PYPL   62.03 (-0.11%)
XOM   120.11 (+1.34%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
(COV) stock logo
COV
(COV)
$0.00
$65.97
$108.57
N/AN/A3.88 million shsN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
$3.53
+7.0%
$2.00
$0.72
$3.63
$141.66M1.29301,206 shs177,563 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
(COV) stock logo
COV
(COV)
0.00%0.00%0.00%0.00%0.00%
Rezolute, Inc. stock logo
RZLT
Rezolute
+1.85%+26.92%+73.68%+230.03%+72.77%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
(COV) stock logo
COV
(COV)
N/AN/AN/AN/AN/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
3.0936 of 5 stars
3.53.00.00.03.84.20.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
(COV) stock logo
COV
(COV)
N/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
3.00
Buy$8.80149.29% Upside

Current Analyst Ratings

Latest RAC, RZLT, BOT, and COV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Rezolute, Inc. stock logo
RZLT
Rezolute
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$7.00
4/18/2024
Rezolute, Inc. stock logo
RZLT
Rezolute
Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
4/9/2024
Rezolute, Inc. stock logo
RZLT
Rezolute
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
3/7/2024
Rezolute, Inc. stock logo
RZLT
Rezolute
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
2/14/2024
Rezolute, Inc. stock logo
RZLT
Rezolute
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
(COV) stock logo
COV
(COV)
N/AN/AN/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/A$3.15 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
(COV) stock logo
COV
(COV)
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
-$51.79M-$1.10N/AN/AN/AN/A-51.81%-48.05%5/9/2024 (Estimated)

Latest RAC, RZLT, BOT, and COV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/13/2024Q2 2024
Rezolute, Inc. stock logo
RZLT
Rezolute
-$0.27-$0.27N/A-$0.27N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
(COV) stock logo
COV
(COV)
N/AN/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
(COV) stock logo
COV
(COV)
N/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
N/A
12.00
12.00

Ownership

Institutional Ownership

CompanyInstitutional Ownership
(COV) stock logo
COV
(COV)
N/A
Rezolute, Inc. stock logo
RZLT
Rezolute
82.97%

Insider Ownership

CompanyInsider Ownership
(COV) stock logo
COV
(COV)
N/A
Rezolute, Inc. stock logo
RZLT
Rezolute
18.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
(COV) stock logo
COV
(COV)
N/AN/AN/ANot Optionable
Rezolute, Inc. stock logo
RZLT
Rezolute
5740.13 million32.83 millionNot Optionable

RAC, RZLT, BOT, and COV Headlines

SourceHeadline
JonesTrading Initiates Coverage of Rezolute (RZLT) with Buy RecommendationJonesTrading Initiates Coverage of Rezolute (RZLT) with Buy Recommendation
msn.com - April 19 at 8:15 AM
Rezolute (NASDAQ:RZLT) Given Market Outperform Rating at JMP SecuritiesRezolute (NASDAQ:RZLT) Given Market Outperform Rating at JMP Securities
marketbeat.com - April 18 at 2:21 PM
Jonestrading Begins Coverage on Rezolute (NASDAQ:RZLT)Jonestrading Begins Coverage on Rezolute (NASDAQ:RZLT)
marketbeat.com - April 18 at 8:35 AM
Optimistic Buy Rating for Rezolute’s RZ402 Drug Candidate Amid Promising DME Treatment ProspectsOptimistic Buy Rating for Rezolute’s RZ402 Drug Candidate Amid Promising DME Treatment Prospects
markets.businessinsider.com - April 18 at 5:30 AM
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
investorplace.com - April 15 at 3:43 PM
Rezolute Stock (NASDAQ:RZLT), Analyst Ratings, Price Targets, PredictionsRezolute Stock (NASDAQ:RZLT), Analyst Ratings, Price Targets, Predictions
benzinga.com - April 10 at 4:10 PM
Rezolute (NASDAQ:RZLT) Receives New Coverage from Analysts at Maxim GroupRezolute (NASDAQ:RZLT) Receives New Coverage from Analysts at Maxim Group
americanbankingnews.com - April 10 at 3:48 AM
Rezolute (NASDAQ:RZLT) Earns Buy Rating from Analysts at Maxim GroupRezolute (NASDAQ:RZLT) Earns Buy Rating from Analysts at Maxim Group
marketbeat.com - April 9 at 8:23 AM
Insiders Are Buying These 5 Penny StocksInsiders Are Buying These 5 Penny Stocks
insidermonkey.com - April 4 at 8:51 AM
Rezolute, Inc. (NASDAQ:RZLT) Short Interest UpdateRezolute, Inc. (NASDAQ:RZLT) Short Interest Update
marketbeat.com - March 27 at 9:30 PM
Rezolute Reaches US$75m Market Cap Benefiting Insider Stock BuyingRezolute Reaches US$75m Market Cap Benefiting Insider Stock Buying
finance.yahoo.com - March 27 at 8:51 AM
3 Stocks Insiders Are Buying That Analysts Love (RZLT)3 Stocks Insiders Are Buying That Analysts Love (RZLT)
insidertrades.com - March 26 at 12:55 PM
Rezolutes chief medical officer buys $18.8k in company stockRezolute's chief medical officer buys $18.8k in company stock
investing.com - March 20 at 5:29 PM
Daron Evans Buys 20,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) StockDaron Evans Buys 20,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock
insidertrades.com - March 20 at 7:32 AM
Rezolute, Inc. (NASDAQ:RZLT) CFO Daron Evans Acquires 20,000 SharesRezolute, Inc. (NASDAQ:RZLT) CFO Daron Evans Acquires 20,000 Shares
marketbeat.com - March 19 at 10:28 AM
Brian Kenneth Roberts Acquires 10,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) StockBrian Kenneth Roberts Acquires 10,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock
insidertrades.com - March 19 at 5:40 AM
Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) Director Buys 36,503 Shares of StockInsider Buying: Rezolute, Inc. (NASDAQ:RZLT) Director Buys 36,503 Shares of Stock
insidertrades.com - March 15 at 11:42 AM
Rezolute, Inc. (NASDAQ:RZLT) CFO Acquires $96,500.00 in StockRezolute, Inc. (NASDAQ:RZLT) CFO Acquires $96,500.00 in Stock
insidertrades.com - March 11 at 7:22 AM
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
globenewswire.com - March 6 at 7:30 AM
Rezolute Stock (NASDAQ:RZLT) Earnings Dates and Earning CallsRezolute Stock (NASDAQ:RZLT) Earnings Dates and Earning Calls
benzinga.com - February 22 at 12:13 PM
Rezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business UpdateRezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
finanznachrichten.de - February 16 at 9:03 AM
Were Keeping An Eye On Rezolutes (NASDAQ:RZLT) Cash Burn RateWe're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate
finance.yahoo.com - February 15 at 7:59 AM
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business UpdateRezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
finance.yahoo.com - February 13 at 7:04 PM
Buy Rating Affirmed for Rezolute’s RZ358 Based on Untapped Market Potential and Therapeutic EfficacyBuy Rating Affirmed for Rezolute’s RZ358 Based on Untapped Market Potential and Therapeutic Efficacy
markets.businessinsider.com - February 8 at 8:52 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

(COV) logo

(COV)

NYSE:COV
Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company's brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. The Company's segments include Medical Devices and United States Medical Supplies. Medical Devices includes marketing of advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. United States Medical Supplies includes products, such as nursing care, medical surgical, SharpSafety and original equipment manufacturer (OEM) products. The Company's products include Surgical Solutions, Vascular Therapies, Respiratory and Patient Care.
Rezolute logo

Rezolute

NASDAQ:RZLT
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.